Growth hormone treatment and risk of recurrence or development of secondary neoplasms in survivors of pediatric brain tumors

Journal of Clinical Neuroscience

Volumn 21, Issue 12, 2014, Pages 2155-2159

  Wanga, Zhi Feng ^a   Chen, Hong Lin ^b  

^a Nantong First People's Hospital   (China)

^b NANTONG UNIVERSITY   (China)

Author keywords

Brain tumor; Children; Growth hormone treatment; Meta analysis; Recurrence; Secondary neoplasm

Indexed keywords

GROWTH HORMONE;

AGE; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; EPENDYMOMA; GENDER; HORMONE SUBSTITUTION; HUMAN; MEDULLOBLASTOMA; META ANALYSIS; METASTASIS; PRIORITY JOURNAL; RECURRENCE RISK; TUMOR RECURRENCE; BIBLIOGRAPHIC DATABASE; BRAIN NEOPLASMS; FEMALE; MALE; NEOPLASM RECURRENCE, LOCAL; PEDIATRICS; STATISTICS AND NUMERICAL DATA; SURVIVOR;

BRAIN NEOPLASMS; DATABASES, BIBLIOGRAPHIC; FEMALE; GROWTH HORMONE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PEDIATRICS; SURVIVORS;

EID: 84922789748     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2014.04.016     Document Type: Article

References (21)

1. Baldwin RT, Preston-Martin S. Epidemiology of brain tumors in childhood-a review. Toxicol Appl Pharmacol 2004;199:118-31.
2. Pollack IF, Jakacki RI. Childhood brain tumors: epidemiology, current management and future directions. Nat Rev Neurol 2011;7:495-506.
3. Ramanan M, Chaseling R. Paediatric brain tumours treated at a single, tertiary paediatric neurosurgical referral centre from 1999 to 2010 in Australia. J Clin Neurosci 2012;19:1387-91.
4. Gleeson HK, Stoeter R, Ogilvy-Stuart AL, et al. Improvements in final height over 25 years in growth hormone (GH)-deficient childhood survivors of brain tumors receiving GH replacement. J Clin Endocrinol Metab 2003;88: 3682-9.
5. Bogazzi F, Ultimieri F, Raggi F, et al. Growth hormone inhibits apoptosis in human colonic cancer cell lines: antagonistic effects of peroxisome proliferator activated receptor-gamma ligands. Endocrinology 2004;145:3353-62.
6. Zeitler P, Siriwardana G. Antagonism of endogenous growth hormonereleasing hormone (GHRH) leads to reduced proliferation and apoptosis in MDA231 breast cancer cells. Endocrine 2002;18:85-90.
7. Barabutis N, Schally AV. Knocking down gene expression for growth hormonereleasing hormone inhibits proliferation of human cancer cell lines. Br J Cancer 2008;98:1790-6.
8. Stangelberger A, Schally AV, Varga JL, et al. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice. Clin Cancer Res 2005;11:49-57.
9. Arslanian SA, Becker DJ, Lee PA, et al. Growth hormone therapy and tumor recurrence. Findings in children with brain neoplasms and hypopituitarism. Am J Dis Child 1985;139:347-50.
10. Clayton PE, Shalet SM, Gattamaneni HR, et al. Does growth hormone cause relapse of brain tumours? Lancet 1987;1:711-3.
11. Rodens KP, Kaplan SL, Grumbach MM, et al. Does growth hormone therapy increase the frequency of tumor recurrence in children with brain tumors? Acta Endocrinologica 1987;116:S188-9.
12. Ogilvy-Stuart AL, Shalet SM. Tumour occurrence and recurrence. Horm Res 1992;38:50-5.
13. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. Ottawa Health Research Institute; 2013. Available from: http://www.ohri.ca/ programs/clinical-epidemiology/oxford.asp (assessed at 10 December, 2013).
14. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in metaanalyses. BMJ 2003;327:557-60.
15. Swerdlow AJ, Reddingius RE, Higgins CD, et al. Growth hormone treatment of children with brain tumors and risk of tumor recurrence. J Clin Endocrinol Metab 2000;85:4444-9.
16. Packer RJ, Boyett JM, Janss AJ, et al. Growth hormone replacement therapy in children with medulloblastoma: use and effect on tumor control. J Clin Oncol 2001;19:480-7.
17. Sklar CA, Mertens AC, Mitby P, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2002;87:3136-41.
18. Ergun-Longmire B, Mertens AC, Mitby P, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 2006;91:3494-8.
19. Karavitaki N, Warner JT, Marland A, et al. GH replacement does not increase the risk of recurrence in patients with craniopharyngioma. Clin Endocrinol (Oxf) 2006;64:556-60.
20. Rohrer TR, Langer T, Grabenbauer GG, et al. Growth hormone therapy and the risk of tumor recurrence after brain tumor treatment in children. J Pediatr Endocrinol Metab 2010;23:935-42.
21. Gurney JG, Kadan-Lottick NS, Packer RJ, et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. Cancer 2003;97:663-73.